Taysha Gene Therapies, Inc. Fair Value Adjustment of Warrants
Taysha Gene Therapies, Inc. (TSHA) reported Fair Value Adjustment of Warrants of $1.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-11
- Taysha Gene Therapies, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was $736.00K.
- Taysha Gene Therapies, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $292.00K.
- Taysha Gene Therapies, Inc. fair value adjustment of warrants for the quarter ending 2025-06-30 was $273.00K.
- Taysha Gene Therapies, Inc. fair value adjustment of warrants for the quarter ending 2025-03-31 was -$102.00K, a 130.27% decline year-over-year.
- Taysha Gene Therapies, Inc. fair value adjustment of warrants for fiscal 2025 was $1.20M.
- Taysha Gene Therapies, Inc. fair value adjustment of warrants for fiscal 2024 was -$16.00K, a 100.05% decline from fiscal 2023.
- Taysha Gene Therapies, Inc. fair value adjustment of warrants for fiscal 2023 was $34.72M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2025-12-31 | $736.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.03M derived: sum of 2 quarters · filed 2026-03-19 | $1.30M derived: sum of 3 quarters · filed 2026-08-11 | $1.20M 10-K · filed 2026-03-19 |
| 2025-09-30 | $292.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $565.00K derived: sum of 2 quarters · filed 2026-08-11 | $463.00K 10-Q · filed 2025-11-04 | $380.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $171.00K 10-Q · filed 2026-08-11 | $88.00K derived: sum of 3 quarters · filed 2026-08-11 | $13.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$102.00K 10-Q · filed 2026-05-06 | -$185.00K derived: sum of 2 quarters · filed 2026-05-06 | -$260.00K derived: sum of 3 quarters · filed 2026-05-06 | -$455.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$158.00K derived: sum of 2 quarters · filed 2026-03-19 | -$353.00K derived: sum of 3 quarters · filed 2026-03-19 | -$16.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | -$75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$270.00K derived: sum of 2 quarters · filed 2025-11-04 | $67.00K 10-Q · filed 2025-11-04 | -$65.67M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $142.00K 10-Q · filed 2025-08-12 | -$65.60M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $337.00K 10-Q · filed 2025-05-15 | -$65.40M derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$65.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $34.72M 10-K · filed 2025-02-26 | ||
| 2023-09-30 | $100.46M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |